sur AMOEBA (EPA:ALMIB)
Amoéba's 2025 Annual Results: Towards commercialization in 2026
On February 23, 2026, Amoéba presented its 2025 annual results, marked by regulatory advancements and intense commercial preparation. The company, a specialist in amoeba-based microbiological solutions, obtained approval for its active substance in Europe and commercial authorization in the United States for its biocontrol product AXPERA. These advancements pave the way for commercialization planned for 2026.
The agreements with Koppert and Syngenta, as well as the awards received, strengthen its credibility. Amoéba invested more heavily in industrial development, impacting a net loss of €8,303,000. The company plans to continue operating until the end of 2026, with guaranteed financial support.
In the cosmetics sector, an agreement has been signed with Oriental Beauty Valley in China, strengthening its position in this market. 2026 is expected to mark the beginning of a gradual commercial expansion for Amoéba.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de AMOEBA